According to Technavio, AI is revolutionizing the global menstrual drugs market, projected to grow at a CAGR of 7.75% between 2024 and 2028. Major drivers include increasing awareness about menstrual health and advancements in medical research. Companies like Pfizer and Myovant Sciences are leading with innovative treatments such as Myfembree, which targets endometriosis-related pain, bolstering the market. Treatments like oral and injectable medications dominate the sector, with hospitals, clinics, and pharmacies as key sales channels.
While AI and drug therapy innovations fuel market growth, challenges arise from the increasing preference for non-drug alternatives, such as herbal supplements, lifestyle changes, and digital health tools. These natural options, gaining popularity due to lower perceived risks, are reshaping consumer behavior, pressuring pharmaceutical companies to adapt.
Regulatory scrutiny of both drug-based and alternative treatments is heightening, as safety and efficacy become critical concerns. Additionally, clinical trials and research into next-generation treatments like gene therapy are advancing, promising future breakthroughs for managing menstrual conditions like dysmenorrhea, endometriosis, and heavy bleeding.
Click here to read the original news story.